Mental Health

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Staff August 6, 2022

Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Staff August 6, 2022

MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...

American Nurses Association Calls for a Swift and Coordinated Response to Contain the Monkeypox Outbreak

Staff August 6, 2022

A widespread outbreak of monkeypox will be yet another stressor on the nursing professionSilver Spring, MD, Aug. 05, 2022 (GLOBE...

Addiction Medicine Doctor Tampa, Florida – Dr. Hardeep Singh Named to Tampa Magazines’ 2022 Top Doctors List

Staff August 6, 2022

Tampa, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The team at Turning Point of Tampa is proud to congratulate Dr. Hardeep...

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

Staff August 4, 2022

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D.,...

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

Staff July 27, 2022

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

Staff July 26, 2022

LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating...

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Staff July 26, 2022

Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...

Entourage Expands Medical Offerings with Launch of New Services and Products

Staff July 26, 2022

Starseed signs with HelloMD’s telehealth network to support high volume of patient consultations Debuts customized patient treatment plans which could...

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors

Staff July 26, 2022

Renowned neuroscience leader to further long-term clinical research strategy and external collaborationsCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion...

Neuronetics and Alleviant Health Centers Announce Exclusive Partnership

Staff July 25, 2022

Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients MALVERN, Pa., July 25, 2022 (GLOBE...

CloudMD Finalizes Review and Settlement of the VisionPros Acquisition

Staff July 22, 2022

VANCOUVER, British Columbia, July 22, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...

VitalHub Corp. Announces Results of Annual General and Special Meeting of Shareholders

Staff July 22, 2022

TORONTO, July 22, 2022 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (the “Company” or “VitalHub”) today reported a summary of...

XIL Health Ranks No. 35 in the 2022 Top 50 Inspiring Workplaces in North America Award

Staff July 21, 2022

The St. Louis-based healthtech company offers benefits like paid parental leave, profit sharing and mental health daysST. LOUIS, July 21,...

Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call

Staff July 19, 2022

MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Staff July 19, 2022

Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access...

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

Staff July 19, 2022

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation...

Mental Health

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

American Nurses Association Calls for a Swift and Coordinated Response to Contain the Monkeypox Outbreak

Addiction Medicine Doctor Tampa, Florida – Dr. Hardeep Singh Named to Tampa Magazines’ 2022 Top Doctors List

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Entourage Expands Medical Offerings with Launch of New Services and Products

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors

Neuronetics and Alleviant Health Centers Announce Exclusive Partnership

CloudMD Finalizes Review and Settlement of the VisionPros Acquisition

VitalHub Corp. Announces Results of Annual General and Special Meeting of Shareholders

XIL Health Ranks No. 35 in the 2022 Top 50 Inspiring Workplaces in North America Award

Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Performant Survey Spotlights Top Healthcare Technology Initiatives

IgniteData Appoints Dr. Jose Galvez as Chief Medical Information Officer to Accelerate Clinical Data Innovation

Ansys to Release First Quarter 2025 Earnings on April 30, 2025

ERPHealth partners with Penn State to help prevent substance use disorder

You may have missed